PREVENT Preclinical Efficacy & Endpoint Biomarkers

Award Notice Posted

Solicitation number
75N91023R00024
Agency
Awarded
to The Univeristy Of Texas M.d. Anderson Cancer Center
Set-aside
No set-aside

Opportunity facts

Contract number
75N91024D00004 Federal IDV award

Notice details come from SAM.gov. Updated .

About this opportunity

The University of Texas MD Anderson Cancer Center was awarded a Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract by the Department of Health and Human Services National Institutes of Health National Cancer Institute in support of the PREVENT Cancer Preclinical Drug Development Program. This indefinite delivery/indefinite quantity contract, awarded on January 24, 2024 for $149,995,000, will provide preclinical efficacy and endpoint biomarkers to aid the PREVENT program over an unspecified contract period.

Notice text

Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract in support of the PREVENT Cancer Preclinical Drug Development Program Awarded contract 75N91024D00004 to THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM for 149995000 on 2024-01-24.

Notice history

6 of 13 notices listed here. See the rest on GovTribe.

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity